Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 129-136 , March 2009

Disseminated intravascular coagulation in cancer patients

  • Marcel Levi, MD (Professor of Medicine, Chairman)

      Affiliations

    • Corresponding Author InformationTel.: +31 20 5662171; Fax: +31 20 6919658.

References 

  1. Levi M. Cancer and DIC. Haemostasis. 2001;31(Suppl. 1):47–48
  2. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:I17–I21
  3. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35:2191–2195
  4. Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Haematol. 2001;106:52–56
  5. Levi M. Cancer and thrombosis. Clin Adv Hematol Oncol. 2003;1:668–671
  6. Sallah S, Wan JY, Nguyen NP, et al. Disseminated intravascular coagulation in solid tumors: clinical and pathological study. Thromb Haemost. 2001;86:828–833
  7. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost. 2001;27:593–604
  8. Sarris AH, Kempin S, Berman E, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood. 1992;79:1305–1310
  9. Avvisati G, ten Cate JW, Sturk A, et al. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol. 1988;70:43–48
  10. Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis. 1998;28(Suppl. 3):50–60
  11. Tallman MS. The thrombophilic state in acute promyelocytic leukemia. Semin Thromb Hemost. 1999;25:209–215
  12. Rodeghiero F, Castaman G. The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. Leukemia. 1994;8(Suppl. 2):S20–S26
  13. Donati MB. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Hemost. 1995;74:278–281
  14. Contrino J, Hair G, Kreutzer DL, et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2:209–215
  15. Rickles FR, Brenner B. Tissue factor and cancer. Semin Thromb Hemost. 2008;34:143–145
  16. Bromberg ME, Konigsberg WH, Madison JF, et al. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A. 1995;92:8205–8209
  17. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94:1320–1327
  18. Nadir Y, Vlodavsky I, Brenner B. Heparanase, tissue factor, and cancer. Semin Thromb Hemost. 2008;34:187–194
  19. Milsom C, Yu J, May L, et al. Diverse roles of tissue factor-expressing cell subsets in tumor progression. Semin Thromb Hemost. 2008;34:170–181
  20. Ishibashi M, Ito N, Fujita M, et al. Endothelin-1 as an aggravating factor of disseminated intravascular coagulation associated with malignant neoplasms. Cancer. 1994;73:191–195
  21. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614–1615
  22. Desai AA, Vogelzang NJ, Rini BI, et al. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95:1629–1636
  23. Kuenen BC, Levi M, Meijers JC, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 2002;22:1500–1505
  24. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002;20:1657–1667
  25. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost. 1999;25:147–155
  26. Walshe LJ, Malak SF, Eagan J, et al. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol. 2002;20:3276–3281
  27. Niers TM, Di NM, Klerk CP, et al. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost. 2007;5:1878–1882
  28. van Wissen S, Bastiaansen BA, Stroobants AK, et al. Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour – a case report. Lupus. 2008;17:586–590
  29. Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol. 1992;19:580–596
  30. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant. 1994;14:495–504
  31. Snyder HW, Mittelman A, Oral A, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer. 1993;71:1882–1892
  32. Guinan EC, Tarbell NJ, Niemeyer CM, et al. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood. 1988;72:451–455
  33. Chappell ME, Keeling DM, Prentice HG, et al. Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?. Bone Marrow Transplant. 1988;3:339–347
  34. Antignac C, Gubler MC, Leverger G, et al. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int. 1989;35:1336–1344
  35. Rabinowe SN, Soiffer RJ, Tarbell NJ, et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood. 1991;77:1837–1844
  36. Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med. 1984;101:41–44
  37. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73:2018–2024
  38. Collins PW, Gutteridge CN, O'Driscoll A, et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant. 1992;10:499–506
  39. Bertomeu MC, Gallo S, Lauri D, et al. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis. 1990;8:511–518
  40. Conway EM, Van de WM, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med. 2002;196:565–577
  41. Levi M, ten Cate JW, Dooijewaard G, et al. DDAVP induces systemic release of urokinase-type plasminogen activator. Thromb Hemost. 1989;62:686–689
  42. Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med. 2002;30:S220–S224
  43. Seeber C, Hiller E, Holler E, et al. Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF alpha)-release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). Thromb Res. 1992;66:373–383
  44. Cohen H, Bull HA, Seddon A, et al. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Haematol. 1989;43:207–214
  45. Charba D, Moake JL, Harris MA, et al. Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies. Am J Hematol. 1993;42:268–277
  46. Franchini M, Montagnana M, Targher G, et al. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost. 2007;33:787–797
  47. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol. 1989;9:2752–2755
  48. Koyama T, Nishida K, Ohdama S, et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol. 1994;87:343–347
  49. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol. 1988;8:5588–5592
  50. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Hemost. 1980;43:77–89
  51. Levi M, van der Poll T, ten Cate H, et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest. 1997;27:3–9
  52. Wada H, Kaneko T, Ohiwa M, et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol. 1993;44:101–105
  53. Pernerstorfer T, Hollenstein U, Hansen J, et al. Heparin blunts endotoxin-induced coagulation activation. Circulation. 1999;100:2485–2490
  54. Corrigan JJJ, Jordan CM. Heparin therapy in septicemia with disseminated intravascular coagulation. N Engl J Med. 1970;283:778–782
  55. Audibert G, Lambert H, Toulemonde F, et al. Use of a low molecular weight heparin, CY 222, in the treatment of consumption coagulopathy, [in French] J Mal Vasc. 1987;12(Suppl. B):147–151
  56. Feinstein DI. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost. 1988;14:351–362
  57. Cook DJ, Crowther MA, Meade MO, et al. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care. 2005;20:309–313
  58. Patel R, Cook DJ, Meade MO, et al. Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care. 2005;20:341–347
  59. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800
  60. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222
  61. Taylor FBJ, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79:918–925
  62. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709
  63. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356:2301–2311
  64. Avvisati G, ten Cate JW, Buller HR, et al. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989;2:122–124
  65. Wheater MJ, Mead GM, Bhandari S, et al. Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma. J Clin Oncol. 2008;26:1008–1010
  66. Shenoy A, Savani BN, Barrett AJ. Recombinant factor VIIa to treat diffuse alveolar hemorrhage following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:622–623
  67. Erikci AA, Ozturk A, Sayan O. Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia. Blood Coagul Fibrinolysis. 2006;17:323–324

PII: S1521-6926(08)00110-2

doi: 10.1016/j.beha.2008.12.005

Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 129-136 , March 2009

Article Tools